We’ve developed Cu-67 and Ac-225 production processes that are non-reactor based. These processes are environmentally preferred and allow for reliable, scalable, commercial quantities.
Technologies that advance the availability of radiopharmaceuticals are increasingly critical for the treatment of cancer. NorthStar’s patient-focused Radiopharmaceutical Contract Development and Manufacturing Organization (CDMO/CMO) addresses this important need.
From in-depth white papers to videos and publications, feel free to delve into the insights presented here and take your journey into game-changing radiopharmaceuticals to new heights.
